Dr Stocker, a Senior Lecturer at the School of Pharmacy, Sydney University, also holds an Honorary Senior Hospital Scientist appointment in the Department of Clinical Pharmacology and Toxicology at St Vincent’s Hospital, Sydney, Australia. Dr Stocker received her PhD from the University of Sydney and performed postdoctoral studies at the University of New South Wales and the University of California San Francisco. Dr Stocker joined the Ethnopharmacology group at GlaxoSmithKline in 2012 and then the Department of Clinical Pharmacology and Toxicology at St Vincent’s Hospital, Sydney in 2015. In 2020, Dr Stocker joined the School of Pharmacy at the University of Sydney. Dr Stocker’s research focuses on understanding variability in response to medicines and how this can be managed to optimise patient care. Her research program involves the application of clinical pharmacology, ethnopharmacology, pharmacogenomics, pharmacometrics, implementation science, health service delivery and qualitative research to optimise medicine use in several therapeutic areas including anti-infectives, gout, diabetes and transplant medicine. She is internationally recognised for implementation of precision dosing software and other precision medicine approaches. Dr Stocker has co-authored more than 120 papers and holds several committee positions in national and international societies. She has gained recognition of leadership internationally (Victor Armstrong Young Investigator Award, 2022), and nationally (CERTARA Young Investigator and the APSA Emerging Leader Award, 2020).

Cornelia Landersdorfer, PhD, is an Associate Professor at the Monash Institute of Pharmaceutical Sciences, Monash University in Melbourne. She trained in clinical PK studies, bioanalysis, PK/PD modelling and microbiological studies in Germany, Australia and the USA. She leads a research group that integrates dynamic in vitro infection experiments with mechanism-based mathematical modelling to optimise dosing of antibiotics and other drugs. Her group performs the design and analysis of clinical and preclinical population PK studies. She is the Academic Deputy Director of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA) which is focused on driving advancements in mRNA medicines. She has >140 peer-reviewed publications, and received the Georgina Sweet Award for Women in Quantitative Biomedical Sciences (2018), the Future Leader Award (2016) and Research Impact Award (2020) in the Faculty of Pharmacy and Pharmaceutical Sciences (#2 worldwide, QS world ranking), a 2022 Australian Award for University Teaching, and the 2023 Monash Graduate Supervisor of the Year award. Invited conference presentations include the European Congress of Clinical Microbiology and Infectious Diseases and American Society of Microbiology Microbe congress. Her research is supported by NHMRC, ARC, NIH and pharmaceutical industry, and has impacted on dosing guidelines and patient therapy internationally.

Kashyap Patel (PhD) is employed by GSK, Australia, where he contributes to model-informed drug development in the department of Clinical Pharmacology Modelling and Simulation. He has over 14 years of experience in pharmacometrics, both in academia and in industry. Kashyap graduated from The University of Auckland in 2009, and has had previous appointments at Monash University, and as a CRO. He has routinely provided quantitative rationale and regulatory support for small molecules and biologics across a range of therapeutic areas, including oncology and infectious diseases. Additionally, he has frequently developed models using adult data with extrapolation to inform paediatric dosing.

Prof Alffenaar is a hospital pharmacist and clinical pharmacologist at the School of Pharmacy, Faculty of Medicine and Health at the University of Sydney. He is member of the leadership team of the University of Sydney Infectious Diseases Institute. He is an internationally recognized expert in PKPD with a special interest in anti-TB agents and current President of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He is a member of the WHO’s Technical Advisory Group on TB drug dosing. Prof Alffenaar led systematic reviews for WHO on the PKPD of second line TB drugs which informed the WHO TB treatment policy review meeting in 2018 and later in 2022. He has significant experience in dose optimization strategies of TB drugs in adults as well as children.